UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

grivet ABCB1

Synonyms: p-glycoprotein

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

No expression data.

In Vitro Substrates

No substrate information.

In Vitro Inhibitors

Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
(+)-devapamil	1.3	Vinblastine	COS-7 cells	Hollt, 1992
(+)-emopamil	3.8	Vinblastine	COS-7 cells	Hollt, 1992
(+)-felodipine	19.6	Vinblastine	COS-7 cells	Hollt, 1992
(+)-isradipine	6.9	Vinblastine	COS-7 cells	Hollt, 1992
(+)-niguldipine	1.1	Vinblastine	COS-7 cells	Hollt, 1992
(+)-nimodipine	5.2	Vinblastine	COS-7 cells	Hollt, 1992
(+)-nitrendipine	5.7	Vinblastine	COS-7 cells	Hollt, 1992
(+)-verapamil	1.6	Vinblastine	COS-7 cells	Hollt, 1992
(-)-devapamil	3.7	Vinblastine	COS-7 cells	Hollt, 1992
(-)-emopamil	3.7	Vinblastine	COS-7 cells	Hollt, 1992
(-)-felodipine	19.2	Vinblastine	COS-7 cells	Hollt, 1992
(-)-isradipine	4	Vinblastine	COS-7 cells	Hollt, 1992
(-)-niguldipine	1.1	Vinblastine	COS-7 cells	Hollt, 1992
(-)-nimodipine	6.7	Vinblastine	COS-7 cells	Hollt, 1992
(-)-nitrendipine	8.6	Vinblastine	COS-7 cells	Hollt, 1992
(-)-verapamil	2.4	Vinblastine	COS-7 cells	Hollt, 1992
B869-60	67.8	Vinblastine	COS-7 cells	Hollt, 1992
B869-61	51.3	Vinblastine	COS-7 cells	Hollt, 1992
Bay K 8644	100	Vinblastine	COS-7 cells	Hollt, 1992
Gallopamil	2.4	Vinblastine	COS-7 cells	Hollt, 1992
Nifedipine	74	Vinblastine	COS-7 cells	Hollt, 1992

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022

Clinical Drug-Drug Interactions

No drug-drug interaction information.